Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ORY-1001||RO7051790|RO 7051790|RG6016|RG 6016|iadademstat||KDM1A Inhibitor 12||ORY-1001 (iadademstat) binds to and inhibits KDM1A (LSD1), leading to increased H3K4 dimethylation and potentially resulting in increased differentiation and decreased growth of tumor cells (PMID: 29502954, PMID: 32191225).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute lymphoblastic leukemia||not applicable||ORY-1001||Preclinical - Pdx||Actionable||In a preclinical study, ORY-1001 reduced leukemic blast percentage and prolonged survival in a T-cell acute lymphoblastic leukemia patient-derived xenograft (PDX) model (PMID: 29502954).||29502954|
|Unknown unknown||acute myeloid leukemia||not applicable||ORY-1001||Phase I||Actionable||In a Phase I trial, ORY-1001 (iadademstat) treatment demonstrated safety in patients with acute myeloid leukemia and resulted in complete remission in one patient and hematologic improvement in 2 additional patients of 27 patients in the dose escalation phase, and resulted in decreased blast percentage and induction of differentiation in patients in the expansion cohort (PMID: 33052756).||33052756|
|Unknown unknown||acute myeloid leukemia||not applicable||ORY-1001||Preclinical - Cell line xenograft||Actionable||In a preclinical study, ORY-1001 decreased colony forming ability in several acute myeloid leukemia (AML) cell lines and primary AML samples in culture, and reduced tumor growth in AML cell line xenograft model (PMID: 29502954).||29502954|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|